Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

Neogenomics (NEO) stock in plain English

Free brief · no signupStart here
NEOPublished Nov 16, 2026
Neogenomics Inc
Healthcare · Diagnostics & Research
Runs specialized clinical laboratories providing molecular, cytogenetic, and pathology testing to oncologists.
Assets:
Fort Myers laboratory hubOperates high-complexity CLIA-certified cancer testing facilities across multiple states.
Specialized medical staffEmploys over one hundred board-certified pathologists and geneticists to interpret tumor tests.
Comprehensive oncology menuProcesses over one million clinical diagnostic tests annually for hospitals and oncology practices.
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

58
OPS ScoreOperating finances
Latest quote
-1.31%$15.09
$1.95B
n/a (loss)
$787.29M

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 16, 2026Quotes updated Nov 20, 04:05 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was NEO. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does Neogenomics (NEO) do?

Neogenomics Inc (NEO) is a U.S.-listed company in Healthcare (Diagnostics & Research). What it does: Runs specialized clinical laboratories providing molecular, cytogenetic, and pathology testing to oncologists. It is worth $1.95B on the market and sold $787.29M over the last year.

Market cap
$1.95B
P/E ratio
None (reported a loss)
Annual sales
$787.29M
Sector
Healthcare
Industry
Diagnostics & Research
Brief updated
Nov 16, 2026

Brands and businesses behind NEO

  • RaDaR: Tracks minimal residual disease using personalized liquid biopsy panels, charging fees to clinical trial sponsors and healthcare providers.
  • Inivata: Develops circulating tumor DNA liquid biopsy technology, generating revenue from oncology research collaborations and clinical test processing.
  • NeoTYPE: Offers targeted multi-gene tumor sequencing profiles, billing insurers and hospitals for analyzing specific solid tumors and blood cancers.

NEO’s flags, in plain English

Each flag is a number from Neogenomics’ reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 16, 2026.

Stupid Cash

Can pay this year's bills 3.5 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.

Low debt

Low debt, only 56% of shareholder equity. The company owes very little compared with what it earns, so a bad year is less likely to force its hand.

Wide Gross Margin

Gross margin of 42.7% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.

Burning Cash

Losing money, profit margin of -4.1%. The business spends more cash than it brings in. It has to cover the gap with cash on hand, new loans or new shares.

2 more green flags and 2 more risk notes open with the free trial. Try it free for 7 days.

Questions about NEO

How big is Neogenomics?

Neogenomics’ market cap is $1.95B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $787.29M: what customers paid the company over the last year, before any costs.

What is NEO’s P/E ratio?

NEO has no P/E ratio right now. The company reported a loss, so there is no yearly profit to price.

What could go wrong with NEO?

Shifts in Medicare and private insurance reimbursement rates reduce the revenue earned per completed test. That is one risk on Neogenomics’ card. Its first risk flag is Burning Cash, explained above. The card holds 2 more risk notes for trial accounts. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From Neogenomics’ own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. NEO’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card